Determination of ethylenediaminetetraacetic acid in sea water by solid-phase extraction and high-performance liquid chromatography

The chelating agent EDTA is widely used, and as a result is showing up widely in the aquatic environment. Here we describe a preconcentration procedure for measuring EDTA concentration in sea water samples by HPLC. The procedure consists of forming an Fe(III) complex followed by solid-phase extraction using an activated carbon cartridge. After the preconcentration, EDTA was quantified by HPLC with ultraviolet detection (260 nm). The enrichment permitted the determination of EDTA at concentrations as low as 1 nM. Good recoveries were obtained for both brackish and full-strength sea water with high repeatability (RSD < 6%). The method was applied to sea water samples taken from near the mouth of the Oyabe River in Japan.     

Further monoterpene chromane esters from Peperomia obtusifolia: VCD determination of the absolute configuration of a new diastereomeric mixture

A reinvestigation of the monoterpene chromane ester enriched fraction from Peperomia obtusifolia using chiral chromatography led to the identification of a minor peak, which was elucidated by NMR and HRMS as fenchyl-3,4-dihydro-5-hydroxy-2,7-dimethyl-8-(3″-methyl-2″-butenyl)-2-(4′-methyl-1′,3′-pentadienyl)-2H-1-benzopyran-6-carboxylate, the same structure assigned to two other fenchyl esters described previously, pointing out a stereoisomeric relationship among them. Further NMR analysis revealed that it was actually a mixture of two compounds, whose absolute configurations were determined by VCD measurements. Although, almost no vibrational transitions could be assigned to the chiral chromane, the experimental VCD spectrum was largely opposite to that obtained for the average experimental VCD [(2S,1?R,2?R,4?S + 2R,1?R,2?R,4?S)/2] for fenchol derivatives. These results allowed us to assign the putative compounds as a racemic mixture of the chiral chromane esterified with the monoterpene (1S,2S,4R)-fenchol, which had not been identified in our early work.     

Characterization of magnetic nanoparticles modified with thiol functionalized PAMAM dendron for DNA recovery

Magnetic nanoparticles (MNPs) modified with the thiol functionalized polyamidoamine (PAMAM) dendron were synthesized to estimate their DNA recovery capabilities. Aminosilane-modified MNPs and MNPs surrounded by a phospholipid (distearoylphosphatidylethanolamine (DSPE)) bilayer were used as core particles. Cystamine-core PAMAM dendrimers were reduced by dithiothreitol to dendron thiols and chemically conjugated to the core particles. Characterization of the synthesis revealed an increase of the surface amine charge from generation 1 (G1) to G6, starting with an aminosilane initiator. Particle size distribution analysis indicated that G6 PAMAM-modified MNPs exhibited monodispersity in an aqueous solution. G6 PAMAM-MNPs and G6 PAMAM-PE-MNPs synthesized by the proposed method have equivalent DNA recovery abilities to PAMAM-MNPs prepared by the conventional divergent synthesis method. In optimized conditions, 96% of λDNA was recovered using G6 PAMAM-PE-MNPs. Therefore, the method for preparing PAMAM-MNPs and PAMAM-PE-MNPs proposed in this study will be a novel approach for producing DNA carriers for efficient DNA purification by magnetic separation.     

5-O-(4-[125 I]Iodobenzyl)-L-ascorbic acid: electrophilic radioiodination and biodistribution in mice

As a part of our efforts to develop potential imaging agents for ascorbate bioactivity, 5-O-(4-[(125)I]iodobenzyl)-L-ascorbic acid ([(125)I]1) was prepared through a two-step sequence which involved radioiodo-destannylation of a protected tributylstannyl precursor 6, followed by hydrolysis in acidic methanol of the protecting groups in 61% overall radiochemical yield, with a radiochemical purity of over 98% and a specific activity of more than 15.4?GBq/μmol. Tissue distribution of [(125)I]1 in tumor-bearing mice showed signs of distribution profiles similar to the reported results for 6-deoxy-6-[(18)F]fluoro-L-ascorbic (6-(18)FAsA) acid and 6-deoxy-6-[(131)I]iodo-L-ascorbic acid (6-(131)IAsA) but with notable differences in the adrenal glands, in which considerably lower uptake of radioactivity and rapid clearance with time were observed. Pretreatment of mice with a known inhibitor of ascorbate transport, sulfinpyrazone, did not produce any significant change in the adrenal uptake of radioactivity after injection of [(125)I]1 compared to the control, suggesting that uptake in the adrenal glands is independent of the sodium-dependent vitamin C transporter 2 transport mechanism. Introduction of a bulky substituent at C-5 on AsA, such as an iodobenzyloxy group, may not be suitable for the design of analogs that may still be able to maintain characteristic distribution properties in vivo seen with AsA itself.     

Long hydrogen-bonded rod of molecular oxide: a hexatantalate tetramer

A tetra-n-butylammonium (TBA) salt of [H(4.5)(Ta(6)O(19))](3.5-) was synthesized by reacting hydrous tantalum oxide with TBAOH. X-ray structural analysis of TBA(3.5)[H(4.5)(Ta(6)O(19))]·2THF·5.5H(2)O (THF = tetrahydrofuran) revealed that this compound consists of a hydrogen-bonded, rod-shaped tetramer of hexatantalate that is almost 30 ? long together with TBA cations and solvent molecules of crystallization [a = 20.6354(5) ?, b = 25.5951(7) ?, c = 37.2058(8) ?, α = 77.092(1)°, β = 86.177(1)°, γ = 88.683(1)°, V = 19110.9(8) ?(3), Z = 8, and space group P ?1]. (1)H NMR spectra showed that this tetrameric structure is maintained in solution.     

Organic vapor triggered repeatable on-off crystalline-state luminescence switching

A nonporous crystalline solid consisting of an organoarsenic platinum(II) complex, i.e., a mononuclear diiodoplatinum(II) complex trans-PtI(2)(cis-DHDAtBu)(2) (1) with cis-1,4-dihydro-1,4-dimethyl-2,3,5,6-tetrakis(tert-butoxycarbonyl)-1,4-diarsinine (cis-DHDAtBu), shows on-off solid-state luminescence switching through reversible solvent vapor uptake and escape. The on-off switching of solid-state luminescence was achieved without changing the structure or electronic state of the organoarsenic platinum(II) complex.     

White light emission from a single component system: remarkable concentration effects on the fluorescence of 1,3-diaroylmethanatoboron difluoride

Concentration effects on the fluorescence (FL) emission of 1,3-dibenzoylmethanatoboron difluoride (1aBF₂) and its diisopropyl derivative (1bBF₂) in KBr and CH₂Cl₂ were investigated. Powder samples of 1aBF₂ and 1bBF₂ in KBr exhibit yellow and white FL emissions, respectively, whose intensities and wavelengths are not significantly affected by concentration. In contrast, remarkable concentration effects on FL properties of these compounds in CH₂Cl₂ solutions were observed. Increases in the concentrations of 1aBF₂ and 1bBF₂ from 1 × 10⁻⁷ to ca. 2 × 10⁻¹ M lead to dramatic changes in the FL colors from blue (398 and 411 nm, respectively) to yellow (548 and 558 nm) via white. Careful analysis of the FL spectra, involving lifetime determinations and wave deconvolutions, reveals that emissions from 1BF₂ involve two FL domains, corresponding to an excited monomer and an excimer, and that concentration increases promote a continuous change from the former to the latter major FL domain. Thus, white FL of 1aBF₂ and 1bBF₂ is achieved by modulation of the dual FL of the excited monomer (blue) and excimer (yellow). These findings indicate that 1,3-diaroylmethanatoboron difluoride (1BF₂) represents a new white emitting material that has advantageous features which arise from the fact that it is an easily prepared, low molecular weight, single component system not containing a heavy metal atom.     

Blockade of inflammatory responses by a small-molecule inhibitor of the Rac activator DOCK2

1. Download : Download high-res image (273KB)
2. Download : Download full-size image

Highlights? CPYPP binds to DOCK2 DHR-2 domain and inhibits its catalytic activity ? CPYPP inhibits DOCK2-mediated Rac activation in cells ? The structural features of CPYPP required for its inhibitory effect were revealed ? CPYPP inhibits lymphocyte migration and activation in vitro and in vivo